Wed, Oct 22, 2014, 3:00 AM EDT - U.S. Markets open in 6 hrs 30 mins

Recent

% | $
Quotes you view appear here for quick access.

Peregrine Pharmaceuticals, Inc. Message Board

  • stockbrokerjoe stockbrokerjoe Jan 31, 2014 8:54 PM Flag

    King Recently Told Minyanville Analysts That He Has Had 15 Meetings With Potential Partners!

    The company plans to continue testing the drug bavituximab as a second-line treatment for lung cancer and it also hopes to move soon to get a partner to help it fund the next phase of clinical trials.

    King recently told Minyanville that he’s had 15 meetings with potential development partners. A partner would help Peregrine pay for the third and final phase of studies generally needed for US approval of a new treatment. King said he hopes to find a partner that would allow Peregrine to retain some of the US sales rights for the drug if it should ever be approved.

    “We are currently in discussions with several potential pharmaceutical partners who have expressed great interest in our bavituximab oncology program,” Peregrine CEO Steven King said in a statement on Friday.

    It's happening!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ah ah ah ... you poor IDIOT ... this statement was made in 2012! ..

      "Peregrine Pharmaceuticals (NASDAQ:PPHM) Hits Multi Month Highs on lung cancer drug trial results

      Share in Peregrine Pharmaceuticals(NASDAQ:PPHM) rose more than 47 percent on Friday as trials of its experimental drug for lung cancer patients showed that patients taking the drug lived twice as many months as those treated with only chemotherapy.

      The company plans to continue testing the drug bavituximab as a second-line treatment for lung cancer and it also hopes to move soon to get a partner to help its fund the next phase of clinical trials.

      King recently told Minyanville that he’s had 15 meetings with potential development partners. A partner would help Peregrine pay for the third and final phase of studies generally needed for US approval of a new treatment. King said he hopes to find a partner that would allow Peregrine to retain some of the US sales rights for the drug if it should ever be approved.

      “We are currently in discussions with several potential pharmaceutical partners who have expressed great interest in our bavituximab oncology program,” Peregrine CEO Steven King said in a statement on Friday.

      IDIOT

    • "In the Phase-1 clinical trials where 121 patients were studied, those who given a lower dose of bavituzimab and the chemotherapy drug docetaxel lived for 11 more months compared to just 5.6 months for patients who were treated with chemo and placebo."

      This is why the FDA gave them fast Track status! Docetaxol (Taxol) is the Rolls Royce of Chemo Therapy for NSLC patients and when combined with bavituximab the patients lived 11 months or longer!! " Bavituximab not only seeks out and destroys the Lung cancer Cells but also stimulates the immune system indirectly in a manner as if the patients were "vaccinated" against their cancer!"

      So King is on record of leaking his plans to merge...Annette Becker is getting the deal together and my best guess is we have an announcement in the next 2-3 weeks just prior to the Oncology meetings so they can announce this to their peers!.

      Sentiment: Strong Buy

 
PPHM
1.48-0.02(-1.33%)Oct 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.